A nonsteroidal glucocorticoid receptor antagonist

Molecular Endocrinology

Volumn 17, Issue 1, 2003, Pages 117-127

  Miner, Jeffrey N ^a   Tyree, Curtis ^a   Hu, Junlian ^a   Berger, Elaine ^a   Marschke, Keith ^a   Nakane, Masaki ^b   Coghlan, Michael J ^b   Clemm, Dave ^a   Lane, Ben ^b   Rosen, Jon ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; D06; DEXAMETHASONE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; LIGAND; MIFEPRISTONE; MINERALOCORTICOID; ONAPRISTONE; PREDNISOLONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CUSHING SYNDROME; DIABETES MELLITUS; HORMONE INHIBITION; MONKEY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STRESS; TRANSCRIPTION REGULATION;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DEXAMETHASONE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; GONANES; HORMONE ANTAGONISTS; HUMANS; NITRO COMPOUNDS; PROTEIN CONFORMATION; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 12244304183     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0010     Document Type: Article

References (70)

1. Gass EK, Leonhardt SA, Nordeen SK, Edwards DP 1998 The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology 139:1905-1919
2. Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai MJ, O'Malley BW 1991 Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 88: 3125-3129
3. Nawaz Z, Tsai MJ, McDonnell DP, O'Malley BW 1992 Identification of novel steroid-response elements. Gene Expr 2:39-47
4. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP 1986 Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 63:639-643
5. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL 1985 Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540
6. Labrie F, Simard J, de Launoit Y, Poulin R, Theriault C, Dumont M, Dauvois S, Martel C, Li SM 1992 Androgens and breast cancer. Cancer Detect Prev 16:31-38
7. Koide SS 1998 Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 43:551-560
8. Anstead GM, Carlson KE, Katzenellenbogen JA 1997 The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268-303
9. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ 1994 Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73: 354-361
10. Adams JB 1998 Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Res Treat 51: 183-188
11. Baulieu EE 1997 RU 486 (mifepristone). A short overview of its mechanisms of action and clinical uses at the end of 1996. Ann NY Acad Sci 828:47-58
12. Clayton LH, Dilley KB 1998 Cushing's syndrome. Am J Nurs 98:40-41
13. Diez JJ 1998 [Pharmacologic treatment of Cushing's syndrome]. Med Clin (Barc) 110:781-796
14. Funder JW 1998 Aldosterone action: fact, failure and the future. Clin Exp Pharmacol Physiol Suppl 25:S47-S50
15. Friedman ZY 1998 Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest 16:391-396
16. Osborne CK 1998 Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
17. Studer UE, Mills RD 1998 Arguments against the long-term use of combined androgen blockade. Eur Urol 34:29-32
18. Schroder FH 1998 Antiandrogens as monotherapy for prostate cancer. Eur Urol 34:12-17
19. Wajsman Z 1998 Arguments for the long-term use of combined androgen blockade. Eur Urol 34:25-28
20. Kong JW, Hamann LG, Ruppar DA, Edwards JP, Marschke KB, Jones TK 2000 Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines. Bioorg Med Chem Lett 10:411-414
21. Zhi L, Tegley CM, Marschke KB, Jones TK 1999 Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg Med Chem Lett 9:1009-1012
22. Higuchi RI, Edwards JP, Caferro TR, Ringenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, Jones TK 1999 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg Med Chem Lett 9:1335-1340
23. Edwards JP, Higuchi RI, Winn DT, Pooley CL, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, Jones TK 1999 Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg Med Chem Lett 9:1003-1008
24. Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK 1999 Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J Med Chem 42:210-212
25. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK 1998 New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 8:745-750
26. Hamann LG, Higuchi RI, Zhi L, Edwards J, Xiao-ning W, Marschke K, Kong J, Farmer L, Jones T 1998 Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J Med Chem 41:623-639
27. Zhi L, Tegley CM, Pio B, West SJ, Marschke KB, Mais DE, Jones TK 2000 Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. Bioorg Med Chem Lett 10:415-418
28. Zhi L, Tegley CM, Marschke KB, Mais DE, Jones TK 1999 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification. J Med Chem 42: 1466-1472
29. Katsumata M, Gupta C, Baker MK, Sussdorf CE, Goldman AS 1982 Diphenylhydantoin: an alternative ligand of a glucocorticoid receptor affecting prostaglandin generation in A/J mice. Science 218:1313-1315
30. Schmidt TJ, Miller-Diener A, Litwack G 1984 β-Lapachone, a specific competitive inhibitor of ligand binding to the glucocorticoid receptor. J Biol Chem 259: 9536-9543
31. Schulte HM, Chrousos GP, Gold PW, Booth JD, Oldfield EH, Cutler Jr JB, Loriaux DL 1985 Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J Clin Invest 75:1781-1785
32. Chrousos GP 1998 Stress as a medical and scientific idea and its implications. Adv Pharmacol 42:552-556
33. Chrousos GP, Gold PW 1998 A healthy body in a healthy mind-and vice versa-the damaging power of "uncontrollable" stress [editorial; comment]. J Clin Endocrinol Metab 83:1842-1845
34. Burgess E, Dorn LD, Haaga DA, Chrousos G 1996 Sociotropy, autonomy, stress, and depression in Cushing syndrome. J Nerv Ment Dis 184:362-367
35. Allan GF, Tsai SY, Tsai MJ, O'Malley BW 1992 Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. Proc Natl Acad Sci USA 89:11750-11754
36. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267: 19513-19520
37. Guido EC, Delorme EO, Clemm DL, Stein RB, Rosen J, Miner JN 1996 Determinants of promoter-specific activity by glucocorticoid receptor. Mol Endocrinol 10: 1178-1190
38. Mahajan DK, London SN 1997 Mifepristone (RU486): a review. Fertil Steril 68:967-976
39. Bindal RD, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA 1988 Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. J Steroid Biochem 31:287-293
40. Delabre K, Guiochon-Mantel A, Milgrom E 1993 In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421-4425
41. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
42. Tanenbaum DM, Wang Y, Williams SP, Sigler PB 1998 Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95:5998-6003
43. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxyterminal tail of the human progesterone receptor. Cell 69:703-713
44. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266-1274
45. Modarress KJ, Opoku J, Xu M, Sarlis NJ, Simons Jr SS 1997 Steroid-induced conformational changes at ends of the hormone-binding domain in the rat glucocorticoid receptor are independent of agonist vs. antagonist activity. J Biol Chem 272:23986-23994
46. DeFranco D, Morris Jr SM, Leonard CM, Gluecksohn-Waelsch S 1988 Metallothionein mRNA expression in mice homozygous for chromosomal deletions around the albino locus. Proc Natl Acad Sci USA 85:1161-1164
47. Prima V, Depoix C, Masselot B, Formstecher P, Lefebvre P 2000 Alteration of the glucocorticoid receptor subcellular localization by nonsteroidal compounds. J Steroid Biochem Mol Biol 72:1-12
48. Lazar G, Lazar Jr G, Husztik E, Duda E, Agarwal MK 1995 The influence of antiglucocorticoids on stress and shock. Ann NY Acad Sci 761:276-295
49. Thurlimann B 1998 Hormonal treatment of breast cancer: new developments. Oncology 55:501-507
50. Nordeen SK, Bona BJ, Beck CA, Edwards DP, Borror KC, DeFranco DB 1995 The two faces of a steroid antagonist: when an antagonist isn't. Steroids. 60: 97-104
51. McDonnell DP, Clevenger B, Dana S, Santiso-Mere D, Tzukerman MT, Gleeson MA 1993 The mechanism of action of steroid hormones: a new twist to an old tale. J Clin Pharmacol 33:1165-1172
52. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
53. Reichman ME, Foster CM, Eisen LP, Eisen HJ, Torain BF, Simons Jr SS 1984 Limited proteolysis of covalently labeled glucocorticoid receptors as a probe of receptor structure. Biochemistry 23:5376-5384
54. Madan AP, DeFranco DB 1993 Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc Natl Acad Sci USA 90:3588-3592
55. Defranco DB, Madan AP, Tang Y, Chandran UR, Xiao N, Yang J 1995 Nucleocytoplasmic shuttling of steroid receptors. Vitam Horm 51:315-338
56. Lindemeyer RG, Robertson NM, Litwack G 1990 Glucocorticoid receptor monoclonal antibodies define the biological action of RU 38486 in intact B16 melanoma cells. Cancer Res 50:7985-7991
57. Segnitz B, Gehring U 1990 Mechanism of action of a steroidal antiglucocorticoid in lymphoid cells. J Biol Chem 265:2789-2796
58. Graham FL, Van der Eb AJ 1973 A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467
59. Pham TA, Hwung YP, Santiso-Mere D, McDonnell DP, O'Malley BW 1992 Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. Mol Endocrinol 6:1043-1050
60. Granner DK, Thompson EB, Tomkins GM 1970 Dexamethasone phosphate-induced synthesis of tyrosine aminotransferase in hepatoma tissue culture cells. Studies of the early phases of induction and of the steroid requirement for maintenance of the induced rate of synthesis. J Biol Chem 245:1472-1478
61. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM 1985 Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318:635-641
62. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ 1994 Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800
63. Grussenmeyer T, Scheidtmann KH, Hutchinson MA, Eckhart W, Walter G 1985 Complexes of polyoma virus medium T antigen and cellular proteins. Proc Natl Acad Sci USA 82:7952-7954
64. Hollenberg SM, Giguere V, Segui P, Evans RM 1987 Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. Cell 49:39-46
65. Eul J, Meyer ME, Tora L, Bocquel MT, Quirin-Stricker C, Chambon P, Gronemeyer H 1989 Expression of active hormone and DNA-binding domains of the chicken progesterone receptor in E coli. EMBO J 8:83-90
66. Summers MD, Smith GA 1987 A manual of methods for baculovirus vectors and insect cell culture procedures. Tex Agric Exp Stn [Bull]. 155
67. Wecksler WR, Norman AW 1979 An hydroxylapatite batch assay for the quantitation of 1α,25-dihydroxyvitamin D3-receptor complexes. Anal Biochem 92:314-323
68. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
69. DeBlasi A, O'Reilly K, Motulsky HJ 1989 Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10:227-229
70. Chen S, Wang J, Yu G, Liu W, Pearce D 1997 Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 272:14087-14092